MONOPAR THERAPEUTICS INC MNPR
COM · Common Stock · CUSIP 61023L108
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersWilmette, IL
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.85.
Trends to Q2 2023
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 11 |
| Q4 2022 | 11 |
| Q1 2023 | 12 |
| Q2 2023 | 9 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 5 | 5 |
| Q1 2023 | 5 | 3 |
| Q2 2023 | 4 | 6 |
Biggest buyers
| MILLENNIUM MANAGEMENT LLC | New | +32.8k |
| Tower Research Capital LLC (TRC) | Added | +3.0k |
| FMR LLC | New | +150 |
| WELLS FARGO & COMPANY/MN | Added | +2 |
Biggest sellers
| NORTHERN TRUST CORP | Sold out | -37.1k |
| KESTRA PRIVATE WEALTH SERVICES, LLC | Sold out | -23.5k |
| UBS Group AG | Sold out | -6.4k |
| ROYAL BANK OF CANADA | Sold out | -5.0k |
| JPMORGAN CHASE & CO | Sold out | -2.4k |
| VANGUARD GROUP INC | Reduced | -800 |
Insider purchases and sales in Q2 2023
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 0 | — | 0 | — | — |
| Q2 2022 | 0 | — | 0 | — | — |
| Q3 2022 | 0 | — | 0 | — | — |
| Q4 2022 | 1 | $49.7k | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 0 | — | 0 | — | — |
None reported in Q2 2023.
Holders, Q2 2023
| Manager | Shares | Change |
|---|---|---|
| VANGUARD GROUP INC 0.00% of their portfolio | 99.2k $84.8k | Reduced -800 |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 41.9k $35.8k | Unchanged |
| MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio | 32.8k $28.0k | New |
| Rappaport Reiches Capital Management, LLC 0.00% of their portfolio | 10.7k $9.1k | Unchanged |
| MORGAN STANLEY 0.00% of their portfolio | 4.0k $3.4k | Unchanged |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 3.7k $3.2k | Added +3.0k |
| FMR LLC 0.00% of their portfolio | 150 $128 | New |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 33 $28 | Added +2 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |